AVITA Medical, Inc.

NASDAQ:RCEL

Medical - Devices

Healthcare
$16.83 -0.25%

+$0.00 today

Market cap
$418.11M
Beta
1.86
P/E (TTM)
-0.0
EPS (TTM)
-$148.45
52W Low $3.22High $7.12

Volume 0.72M

Average 0.24M

RCEL Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

AVITA Medical, Inc.NASDAQ: RCEL

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables turns negative

Q1 FY2026 accounts payables was -$1.79M, compared with $2.33M a year earlier. Trailing-twelve-month accounts payables was -$1.37M. Over 3 fiscal years it compounded at +113.5% a year.

Context

  • Accounts payables amounted to 3.8% of revenue in FY2025, up 3.3 pp from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts payables holds near -$1.79M or moves back toward the trailing-twelve-month quarterly average of -$342.75K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.79M-281.7% QoQ
Last fiscal yearDec 2025
$2.75M+707.4% YoY
LTMMar 2026
-$1.37M-139.9% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-176.7%——
1 year+707.4%——
3-year CAGR+113.5%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
2.75M USD
Year-over-year change
+707.4%

Accounts Payables vs competitors

How RCEL compares with its peers on the latest reported figures

  • RCEL's LTM Mar 2026 accounts payables of $1.37M is the 3rd largest of the 9 companies compared; the peer median is $262.5K.
  • Its year-over-year change of -139.9% is the lowest of 9, against a peer median of +173.2%.
  • Accounts payables amounts to 1.9% of revenue for RCEL, versus a peer median of 4.9%.
RCEL Competitors Peer median
Accounts Payables for RCEL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OVIDOvid Therapeutics Inc.LTM Mar 2026$3.63M +320.5%-38.0%51.0%
HYPRHyperfine, Inc.LTM Mar 2026$2.33M +1131.4%—15.2%
RCELAVITA Medical, Inc.LTM Mar 2026$1.37M -139.9%+113.5%1.9%
FONRFONAR CorporationLTM Mar 2026$1.06M +335.4%+20.7%1.0%
XTNTXtant Medical Holdings, Inc.LTM Mar 2026$586K +67.9%—0.5%
STTKShattuck Labs, Inc.LTM Mar 2026$343K -64.3%-51.8%34.3%
APYXApyx Medical CorporationLTM Mar 2026$275K +34.1%+74.3%0.5%
LUCDLucid Diagnostics Inc.LTM Mar 2026$250K +278.6%-15.3%4.9%
VANIVivani Medical, Inc.LTM Mar 2026$36K -90.9%-51.5%—
Peer median (excluding RCEL) $262.5K+173.2%-26.7%4.9%

Competitors are the stored peer set for RCEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(25.14M)(26.67M)(35.38M)(61.85M)(48.59M)
Depreciation & Amortization969K568K632K1.13M2.04M
Deferred Income Tax00000
Stock-Based Compensation6.33M7M8.38M13.5M9.52M
Change in Working Capital(1.73M)(1.2M)(6.57M)(4.68M)3.44M
Accounts Receivables(1.19M)(985K)(3.3M)(4.17M)3.63M
Inventory(144K)(371K)(3.69M)(2.16M)(468K)
Accounts Payables0282K809K340K2.75M
Other Working Capital(391K)(122K)(386K)1.31M(2.47M)
Other Non-Cash Items1.53M1.21M(5.07M)2.96M2.4M
Operating Cash Flow(18.04M)(19.09M)(38.01M)(48.94M)(31.2M)
Capital Expenditures(487K)(525K)(1.45M)(9.33M)(1.74M)
Acquisitions (Net)00000
Purchases of Investments0(74.36M)(78.76M)(24.5M)(13.31M)
Sales of Investments055.56M81.81M71.2M27.5M
Other Investing Activities(49.72M)(73K)(66K)(162K)(734K)
Investing Cash Flow(50.21M)(19.33M)1.61M37.36M12.45M
Debt Repayment(11K)038.76M00
Common Stock Issued000014.14M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities64.08M900K1.61M3.51M795K
Financing Cash Flow64.07M900K40.37M3.51M14.94M
Effect of Forex Changes41.29M(26K)(16K)00
Net Change in Cash37.11M(37.55M)3.95M(8.07M)(3.81M)
Free Cash Flow(18.52M)(19.62M)(39.46M)(58.27M)(32.93M)

AVITA Medical, Inc.

NASDAQ:RCEL

Intrinsic Alpha fair value

Locked

Current Price

$16.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.